• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Squalamine earns closer look as wet AMD aid.

Article

Plymouth Meeting, PA-Genaera Corp. is expanding its third U.S. phase II clinical trial of squalamine, its small-molecule, anti-angiogenic drug for the treatment of wet age-related macular degeneration (AMD).

Plymouth Meeting, PA-Genaera Corp. is expanding its third U.S. phase II clinical trial of squalamine, its small-molecule, anti-angiogenic drug for the treatment of wet age-related macular degeneration (AMD).

The expanded trial will offer further analysis of a 10-mg dose of squalamine, which is designed to enhance the work of verteporfin (Visudyne, Novartis Ophthalmics/QLT) treatment by inhibiting the detrimental effects of the VEGF "burst" that commonly occurs after verteporfin use.

The trial was originally designed to test 20- and 40-mg doses, however early results of another phase II trial indicated the need to study a 10-mg dose.

In related news, the company announced Sept. 30 it has received a $100,000 Small Business Innovation Research grant from the National Eye Institute to develop squalamine-related aminosterols further as next-generation, anti-angiogenic medicines for the treatment of wet AMD.

The grant will help Genaera evaluate analogs of squalamine to identify additional compounds with improved features as potential second-generation therapies for treating wet AMD.

"Our goal is to use this program-specific funding to identify and develop orally bio-available anti-angiogenic aminosterols for both AMD and cancer indications," said Roy C. Levitt, MD, Genaera's president and chief executive officer.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2024 MJH Life Sciences

All rights reserved.